Replies to post #3116 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Aeon’s corporate_slide_set_contains_info_about_the_botulinum-toxin_market,_approved_indications,_and_indications_being_pursued by each competitor:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Aeon, the former parent company of EOLS, seeks to develop ABP-450—the exact same toxin as EOLS’ Jeuveau (sole-sourced by Korea’s Daewoong)—for therapeutic indications in the US. Aeon is trying to go public via a SPAC merger with PMGM (#msg-170682391), but closing of the merger has been delayed, suggesting some problems with obtaining shareholder approval (https://www.sec.gov/ix?doc=/Archives/edgar/data/1837607/000110465923018664/tm236357d1_8k.htm ).

p.s. I was not previously aware of Aeon’s pursuit of a PTSD indication, which seems like a longshot.